Cemacabtagene ansegedleucel, an allogeneic chimeric antigen receptor (CAR) T-cell therapy, is being investigated in relapsed/refractory large B-cell lymphoma. The investigational allogeneic chimeric ...
Qihan Biotech receives US FDA’s IND clearance for a universal dual-target CAR-T candidate, QT-019C: Hangzhou, China Friday, May 22, 2026, 12:00 Hrs [IST] Qihan Biotech, a clinic ...
Presented improved editing data in non-human primates (NHP) for sickle cell disease (SCD), demonstrating a single dose of Gene Writer achieved an ...
Much of the challenge in developing cancer therapies is determining methods to improve the effectiveness of the immune system’s ability to identify and kill cancer cells. While therapies like CAR T ...
CD7 is an attractive target for chimeric antigen receptor (CAR) T-cell therapy in relapsed or refractory T-cell acute lymphoblastic leukemia (ALL). Supportive results of first-in-human studies of base ...
CRISPR-edited tumor-infiltrating lymphocytes are emerging as a promising alternative to CAR T-cell therapy for solid cancers.
New approach recruits the body’s immune system to attack glioblastoma while reducing treatment-related toxicity.
Renier Brentjens, MD, PhD, one of the pioneers in the development of chimeric antigen receptor (CAR) T-cell therapy, is poised to see the technology take its next big leap, with researchers testing ...
Scientists have discovered that T cell receptors activate through a hidden spring-like motion that had never been seen before. This breakthrough may help explain why immunotherapy works for some ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results